Quarterly EPS Estimate For Array BioPharma Inc. (NASDAQ:ARRY) Cited At $-0.2


The average EPS estimate for Array BioPharma Inc. (NASDAQ:ARRY) for the three months ending 2016-12-31 is given as $-0.2.

You find that 7 days ago, the average EPS estimate on the stock was $-0.2, while for the 30 days ago the average EPS estimate stood at $-0.2.

If you look back further, you see that the average EPS estimate for Array BioPharma Inc. (NASDAQ:ARRY) 60 days ago was given as -0.2, while EPS estimate 90 days ago was quoted at $-0.2.

The change in the stock’s EPS estimate over the last 7 days works out to 0%.

EPS estimate revisions

Over the last 7 days, EPS estimates for Array BioPharma Inc. (NASDAQ:ARRY) have been revised up 0 times. In the same period, the EPS estimate has been revised down 0 times.

In the last 30 days, the stock has had its EPS estimate revised up 0 and it has been revised up 0 times over the last 60 days.

Up revisions in the last 90 days are 0 and up revisions in the last 120 days are 0.

But for the last 18 days, the company has seen its EPS revised up 0 times, offset by 0 down revisions in the same period.

The down revisions of EPS in last 30, 60, 90 and 120 days were 1, 1, 1 and 0.

What About EPS Surprises

Analysts predicted EPS of $-0.2 for Array BioPharma Inc. (NASDAQ:ARRY) for the period ended 4. But the company ended up posting actual EPS of $-0.17 on 2016-08-04. The EPS estimate cited was worked out based on 6 estimates that analysts had issued on the stock.

Therefore, Array BioPharma Inc. (NASDAQ:ARRY) posted EPS surprise of $-0.02 per share in dollar terms, which works out to -13.33%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.13.

Quarterly Sales Estimates

For the fiscal year 2017, the mean and median annual sales estimates for the company are given as $56.32 and $58.71. The estimates are based on the projections of 3 analysts.

So far, the highest annual sales estimate for Array BioPharma Inc. (NASDAQ:ARRY) stands at$67.1. That compares with the lowest annual sales estimate of $43.15. Calculating the standard deviation of the extreme annual sales estimates leads you to 12.152%.

Annual sales estimate adjustments

In the last 7 days, 3 analysts have raised their annual sales estimates for the company. But over the same period, 3 analysts have trimmed their annual sales estimates.

With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to 0%.

Over the last one month, though, 3 analysts moved to raise their sales estimates for Array BioPharma Inc. (NASDAQ:ARRY). That compares with 3 analysts who cut their sales estimate for the company in the same period. That leads you to 133.499% as the mean sales estimate change over the last one month.

If you look back further, you see that over the last three months, 3 analysts have moved raise their sales estimates Array BioPharma Inc. (NASDAQ:ARRY). That offset by 3 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of 133.499% over a period of three months.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 24 times, 1 visits today)